Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Duensing

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|October 1, 1996
Linomide and interleukin-2 in patients with advanced renal cell carcinomaM Deckert, A Franzke, J Buer, et al.
British Journal of Cancer|July 14, 1998
Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanomaA Franzke, M Probst-Kepper, J Buer, et al.
British Journal of Cancer|January 1, 1997
Elevated serum levels of S100 and survival in metastatic malignant melanomaJ Buer, M Probst, A Franzke, et al.
Anticancer Research|January 1, 1995
In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2M Meffert, A Schomburg, E L Hänninen, et al.
Invasion & Metastasis|January 1, 1996
Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell lineS Duensing, F Brevis Nunez, N Meyer, et al.
Cytokines and Molecular Therapy|March 1, 1995
Lymphocyte-conditioned medium in combination with interleukin-2 effectively induces antitumour autoimmunity by adoptive transfer of short activated killer (SHAK) cellsJ Buer, R Hilse, I Dallmann, et al.
Oncology|July 1, 1994
Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patientsS Duensing, I Dallmann, J Grosse, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1995
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifenJ Atzpodien, E Lopez Hänninen, H Kirchner, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1996
Cytogenetic studies in renal cell carcinoma patients receiving low-dose recombinant interleukin-2-based immunotherapyS Duensing, E van den Berg-de Ruiter, S Störkel, et al.
Cancer Biotherapy|January 1, 1994
In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2M Meffert, E L Hanninen, T Menzel, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Cancer Biotherapy & Radiopharmaceuticals|October 1, 1996
Linomide and interleukin-2 in patients with advanced renal cell carcinomaM Deckert, A Franzke, J Buer, et al.
British Journal of Cancer|July 14, 1998
Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanomaA Franzke, M Probst-Kepper, J Buer, et al.
British Journal of Cancer|January 1, 1997
Elevated serum levels of S100 and survival in metastatic malignant melanomaJ Buer, M Probst, A Franzke, et al.
Anticancer Research|January 1, 1995
In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2M Meffert, A Schomburg, E L Hänninen, et al.
Invasion & Metastasis|January 1, 1996
Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell lineS Duensing, F Brevis Nunez, N Meyer, et al.
Cytokines and Molecular Therapy|March 1, 1995
Lymphocyte-conditioned medium in combination with interleukin-2 effectively induces antitumour autoimmunity by adoptive transfer of short activated killer (SHAK) cellsJ Buer, R Hilse, I Dallmann, et al.
Oncology|July 1, 1994
Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patientsS Duensing, I Dallmann, J Grosse, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1995
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifenJ Atzpodien, E Lopez Hänninen, H Kirchner, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1996
Cytogenetic studies in renal cell carcinoma patients receiving low-dose recombinant interleukin-2-based immunotherapyS Duensing, E van den Berg-de Ruiter, S Störkel, et al.
Cancer Biotherapy|January 1, 1994
In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2M Meffert, E L Hanninen, T Menzel, et al.
Pageof 8